FBXO22 and cancer: In circumstances with low E1 and E2 levels, Fbxo22, as a negative regulator disassembling KDB4B, might not be required to maintain the homeostasis of ER-positive cancer cells, resulting in Fbxo22 being naturally downregulated in ILCs in postmenopausal women.